Boceprevir

波西普韦

Report date: 2022/08/17 14:30:30
NMEFirst In Class

Base Information

Drug NameBoceprevir
Drug Alias Name博赛泼维boceprevirum柏塞瑞韦波普瑞韦博赛泼韦 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsHepatitis C, ChronicHepatitis CHIV Infections
Global Approved IndicationsHepatitis C, ChronicHepatitis C
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2011/05/13
Country/TerritoryUnited StatesUnited KingdomFrance +[5] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaPending
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of LiverpoolMerck & Co IncUniversity Of Turin +[5] 
Active IndicationsN/A
Inactive IndicationsHepatitis C, ChronicHepatitis CHIV Infections

Other Information

ATC CodeJ05AP03
Related LinksWikipediaDrugBankKEGG